SCIENTIFIC PROGRAMME
SESSION I
BIOLOGY OF B-CELL
PRECURSOR ALL
SESSION II
BIOLOGY OF T-CELL ALL
SESSION III
MINIMAL RESIDUAL
DISEASE MONITORING
SESSION IV
INDIVIDUALIZED
MANAGEMENT OF ALL
SESSION V
NEW ADVANCES IN ALL
SESSION VI
CAR T-CELLS &
ALLOGENEIC HSCT
SESSION VII
FRONTLINE
INCORPORATION OF
BITES AND ADCS
SESSION VIII
T-CELL ALL AND
LYMPHOBLASTIC
LYMPHOMA
SESSION IX
PH AND PH-LIKE ALL
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
AS E-POSTERS
DISCLOSURES
11. Rheingold SR, Ji L, Xu X, et al. Prognostic factors for survival after relapsed acute lymphoblastic leukemia
(ALL): A Children’s Oncology Group (COG) study. 2019;37(15_suppl):10008-10008.
12. Gossai N, Winter SS, Devidas M, et al. Nelarabine Abrogates Relapse Rates in CNS3 T-ALL: A Report from
Children's Oncology Group Study AALL0434. SIOP ABSTRACTS. 2019;66(S4):e27989.
13. Wood BL, Winter SS, Dunsmore KP, et al. T-Lymphoblastic Leukemia (T-ALL) Shows Excellent Outcome,
Lack of Significance of the Early Thymic Precursor (ETP) Immunophenotype, and Validation of the Prognostic
Value of End-Induction Minimal Residual Disease (MRD) in Children’s Oncology Group (COG) Study AALL0434.
Blood. 2014;124(21):1-1.
14. Schrappe M, Valsecchi MG, Bartram CR, et al. Late MRD response determines relapse risk overall and in
subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood. 2011;118(8):2077-2084.
15. Schrappe M, Hunger SP, Pui CH, et al. Outcomes after induction failure in childhood acute lymphoblastic
leukemia. N Engl J Med. 2012;366(15):1371-1381.
16. Dunsmore KP, Winter S, Devidas M, et al. COG AALL0434: A randomized trial testing nelarabine in newly
diagnosed t-cell malignancy. 2018;36(15_suppl):10500-10500.
17. Winter SS, Devidas M, Wood B, et al. Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) for
Children and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) Treated at Investigator Discretion:
A Report from Children's Oncology Group (COG) AALL0434. Blood. 2018;132(Supplement 1):659-659.
18. Teachey DT, Pui CH. Comparative features and outcomes between paediatric T-cell and B-cell acute
lymphoblastic leukaemia. Lancet Oncol. 2019;20(3):e142-e154.
19. Zhang J, Ding L, Holmfeldt L, et al. The genetic basis of early T-cell precursor acute lymphoblastic
leukaemia. Nature. 2012;481(7380):157-163.
20. Conter V, Valsecchi MG, Buldini B, et al. Early T-cell precursor acute lymphoblastic leukaemia in children
treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis. Lancet Haematol. 2016;3(2):e80-
86.
21. Coustan-Smith E, Mullighan CG, Onciu M, et al. Early T-cell precursor leukaemia: a subtype of very high-risk
acute lymphoblastic leukaemia. Lancet Oncol. 2009;10(2):147-156.
22. Patrick K, Wade R, Goulden N, et al. Outcome for children and young people with Early T-cell precursor
acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. Br J Haematol.
2014;166(3):421-424.
23. Liu Y, Easton J, Shao Y, et al. The genomic landscape of pediatric and young adult T-lineage acute
lymphoblastic leukemia. Nat Genet. 2017;49(8):1211-1218.
24. Petit A, Trinquand A, Chevret S, et al. Oncogenetic mutations combined with MRD improve outcome
prediction in pediatric T-cell acute lymphoblastic leukemia. Blood. 2018;131(3):289-300.